[Piperacillin-tazobactam in continuous or expanded perfusion vs intermittent perfusion].

Area of Science:

• Pharmacology
• Infectious Diseases
• Critical Care Medicine

Background:

• Piperacillin-tazobactam is a critical antibiotic for treating severe bacterial infections.
• Optimizing antibiotic administration is crucial for patient outcomes and combating antimicrobial resistance.

Purpose of the Study:

• To compare the efficacy, safety, pharmacokinetics, pharmacodynamics, and cost-effectiveness of continuous/expanded versus intermittent piperacillin-tazobactam perfusion.
• To determine the optimal administration strategy for piperacillin-tazobactam.

Main Methods:

• Systematic review of bibliographic searches.
• Inclusion of 6 relevant studies from an initial pool of 38.
• Analysis of study design, treatment groups, patient numbers, and collected variables.

Main Results:

• Continuous/expanded perfusion showed significantly better outcomes in two studies, favoring reduced mortality and improved clinical recovery.
• Specific studies demonstrated marked differences in mortality rates and clinical recovery between the two administration methods.
• One study indicated a potential cost-effectiveness advantage for continuous/expanded perfusion.

Conclusions:

• Continuous/expanded piperacillin-tazobactam perfusion appears to be at least as effective as, and potentially more effective than, intermittent administration.
• This method may be particularly beneficial for severe infections caused by resistant pathogens like Pseudomonas aeruginosa.
• Continuous/expanded perfusion presents a theoretically more cost-effective administration strategy.